In the first part of “Topical Conversations: Bright Spots,” a three-part series discussing tapinarof, an innovative nonsteroidal topical treatment for plaque psoriasis, particularly effective in the head and neck region, G. Michael Lewitt, MD, and James Del Rosso, DO, delve into tapinarof’s unique mechanism as an aryl hydrocarbon receptor (AhR) agonist. This naturally derived treatment restores skin barrier function, downregulates proinflammatory cytokines like IL-17 and IL-22, and maintains skin homeostasis. The PSOARING 3 trial showed a remittive effect after treatment cessation, with patients maintaining clear skin for around four months post-treatment.

A phase 4 open-label trial focused on head and neck psoriasis underscored tapinarof’s efficacy, with significant improvement in lesion scores and a high percentage of patients achieving clear or almost clear skin. This trial reported no new safety concerns, highlighting its potential as a versatile, well-tolerated option for patients with varying severity of psoriasis, especially challenging areas like the scalp. The findings from these trials emphasize tapinarof’s potential in real-world clinical practice, offering a cosmetically appealing alternative to traditional psoriasis treatments.

Reference: Bright Spots: Tapinarof for Plaque Psoriasis of the Head and Neck. Dermsquared. Published March 1, 2024. Accessed March 29, 2024. https://dermsquared.com/videos/topical-conversations/bright-spots-1?utm_source=mailchimp&utm_medium=email&utm_campaign=240308-sts